tirzepatide heart attack for Failure in Patients with Obesity Tirzepatide Reduces Heart Failure Risk

Semaglutide, a GLP-1 receptor agonist, is the active substance in certain medicines used in the treatment of diabetes and obesity (namely Ozempic, Rybelsus and Wegovy)

Traditional weight loss diets often lead to initial success but frequently result in relapse and weight regain due to increased hunger pangs

2021 (World Health Organization, accessed 16 February 2024)

Going from Tirzepatide to Semaglutide If Tirzepatide isnt delivering the desired results or causing side effects, transitioning back to Semaglutide may provide better weight management

We are not your primary care physician and do not replace the need for a personal medical doctor